Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Z Wong

Showing results (191-200 of 198) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 198 results.
Neuro-Oncology|April 12, 2008
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumorsJohn H Sampson, Gamal Akabani, Gerald E Archer, et al.
Neuro-Oncology|February 22, 2008
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boostDavid A Reardon, Michael R Zalutsky, Gamal Akabani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2005
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study resultsDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomasDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 3, 2006
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial resultsDavid A Reardon, Jennifer A Quinn, Gamal Akabani, et al.
Oncoimmunology|May 1, 2023
Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanomaJorge D Oldan, Benjamin C Giglio, Eric Smith, et al.
Clinical Genitourinary Cancer|March 10, 2020
Pilot Study of [<sup>18</sup>F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC)Patrick J Eulitt, Ersan Altun, Arif Sheikh, et al.
Geroscience|January 31, 2025
Dynamic proportional loss of functional connectivity revealed change of left superior frontal gyrus in subjective cognitive decline: an explanatory study based on Chinese and Western cohortsLuyao Wang, Wenjing Hu, Fan Dong, et al.
Pageof 20

Showing results (191-200 of 198) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 198 results.
Neuro-Oncology|April 12, 2008
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumorsJohn H Sampson, Gamal Akabani, Gerald E Archer, et al.
Neuro-Oncology|February 22, 2008
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boostDavid A Reardon, Michael R Zalutsky, Gamal Akabani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2005
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study resultsDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomasDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 3, 2006
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial resultsDavid A Reardon, Jennifer A Quinn, Gamal Akabani, et al.
Oncoimmunology|May 1, 2023
Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanomaJorge D Oldan, Benjamin C Giglio, Eric Smith, et al.
Clinical Genitourinary Cancer|March 10, 2020
Pilot Study of [<sup>18</sup>F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC)Patrick J Eulitt, Ersan Altun, Arif Sheikh, et al.
Geroscience|January 31, 2025
Dynamic proportional loss of functional connectivity revealed change of left superior frontal gyrus in subjective cognitive decline: an explanatory study based on Chinese and Western cohortsLuyao Wang, Wenjing Hu, Fan Dong, et al.
Pageof 20